Published 2022
| Version v1
Publication
Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP)
Creators
- Passaro, Antonio
- Russo, Giuseppe Lo
- Passiglia, Francesco
- D'Arcangelo, Manolo
- Sbrana, Andrea
- Russano, Marco
- Bonanno, Laura
- Giusti, Raffaele
- Metro, Giulio
- Bertolini, Federica
- Grisanti, Salvatore
- Carta, Annamaria
- Cecere, Fabiana
- Montrone, Michele
- Massa, Giacomo
- Perrone, Fabiana
- Simionato, Francesca
- Guaitoli, Giorgia
- Scotti, Vieri
- Genova, Carlo
- Lugini, Antonio
- Bonomi, Lucia
- Attili, Ilaria
- de Marinis, Filippo
Contributors
Others:
- Passaro, Antonio
- Russo, Giuseppe Lo
- Passiglia, Francesco
- D'Arcangelo, Manolo
- Sbrana, Andrea
- Russano, Marco
- Bonanno, Laura
- Giusti, Raffaele
- Metro, Giulio
- Bertolini, Federica
- Grisanti, Salvatore
- Carta, Annamaria
- Cecere, Fabiana
- Montrone, Michele
- Massa, Giacomo
- Perrone, Fabiana
- Simionato, Francesca
- Guaitoli, Giorgia
- Scotti, Vieri
- Genova, Carlo
- Lugini, Antonio
- Bonomi, Lucia
- Attili, Ilaria
- de Marinis, Filippo
Description
The selective RET-inhibitor pralsetinib has shown therapeutic activity in early clinical trials in patients with non-small cell lung cancer (NSCLC) harboring rearranged during transfection (RET) gene fusions. To date, the real-world efficacy of pralsetinib in this population is unknown.
Additional details
Identifiers
- URL
- https://hdl.handle.net/11567/1101654
- URN
- urn:oai:iris.unige.it:11567/1101654
Origin repository
- Origin repository
- UNIGE